Maryam Shirzadi, Negin Farshchian, Arash Nazarpour, Soudabeh Eskandari, Fahimeh Kahrari, Hamed Abdollahpour Ranjbar, Somayeh Nazari, Issa Hekmati, Sara Farhang
{"title":"艾司西酞普兰和渐进式肌肉放松训练对治疗乳腺癌患者潮热都有效:一项随机对照试验。","authors":"Maryam Shirzadi, Negin Farshchian, Arash Nazarpour, Soudabeh Eskandari, Fahimeh Kahrari, Hamed Abdollahpour Ranjbar, Somayeh Nazari, Issa Hekmati, Sara Farhang","doi":"10.1080/0167482X.2021.1985452","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Available treatments for hot flashes in patients with breast cancer are not always tolerable or effective for all patients.</p><p><strong>Methods: </strong>Patients diagnosed to have primary breast cancer were randomly allocated to receive 10<b> </b>mg of escitalopram, placebo, or progressive muscle relaxation therapy. Patients were asked to report the frequency and duration of hot flashes during day and night, at baseline and after ten weeks of treatment, and completed the menopause rating scale.</p><p><strong>Results: </strong>Eighty-two patients were randomly assigned to receive escitalopram (<i>n</i><b> </b>=<b> </b>26), PMRT (<i>n</i><b> </b>=<b> </b>28), and placebo (<i>n</i><b> </b>=<b> </b>28). PMRT and escitalopram could effectively decrease number and duration of diurnal and nocturnal HFs in patients with breast cancer, with a better effect observed from escitalopram. They could both decrease the total score of MRS.</p><p><strong>Conclusion: </strong>Both escitalopram ad PMRT can reveal nocturnal and diurnal HFs in terms of frequency and duration in patients with breast cancer.</p>","PeriodicalId":50072,"journal":{"name":"Journal of Psychosomatic Obstetrics & Gynecology","volume":"43 4","pages":"393-399"},"PeriodicalIF":2.1000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Escitalopram and progressive muscle relaxation training are both effective for the treatment of hot flashes in patients with breast cancer: a randomized controlled trial.\",\"authors\":\"Maryam Shirzadi, Negin Farshchian, Arash Nazarpour, Soudabeh Eskandari, Fahimeh Kahrari, Hamed Abdollahpour Ranjbar, Somayeh Nazari, Issa Hekmati, Sara Farhang\",\"doi\":\"10.1080/0167482X.2021.1985452\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Available treatments for hot flashes in patients with breast cancer are not always tolerable or effective for all patients.</p><p><strong>Methods: </strong>Patients diagnosed to have primary breast cancer were randomly allocated to receive 10<b> </b>mg of escitalopram, placebo, or progressive muscle relaxation therapy. Patients were asked to report the frequency and duration of hot flashes during day and night, at baseline and after ten weeks of treatment, and completed the menopause rating scale.</p><p><strong>Results: </strong>Eighty-two patients were randomly assigned to receive escitalopram (<i>n</i><b> </b>=<b> </b>26), PMRT (<i>n</i><b> </b>=<b> </b>28), and placebo (<i>n</i><b> </b>=<b> </b>28). PMRT and escitalopram could effectively decrease number and duration of diurnal and nocturnal HFs in patients with breast cancer, with a better effect observed from escitalopram. They could both decrease the total score of MRS.</p><p><strong>Conclusion: </strong>Both escitalopram ad PMRT can reveal nocturnal and diurnal HFs in terms of frequency and duration in patients with breast cancer.</p>\",\"PeriodicalId\":50072,\"journal\":{\"name\":\"Journal of Psychosomatic Obstetrics & Gynecology\",\"volume\":\"43 4\",\"pages\":\"393-399\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Psychosomatic Obstetrics & Gynecology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/0167482X.2021.1985452\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Psychosomatic Obstetrics & Gynecology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/0167482X.2021.1985452","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
Escitalopram and progressive muscle relaxation training are both effective for the treatment of hot flashes in patients with breast cancer: a randomized controlled trial.
Introduction: Available treatments for hot flashes in patients with breast cancer are not always tolerable or effective for all patients.
Methods: Patients diagnosed to have primary breast cancer were randomly allocated to receive 10mg of escitalopram, placebo, or progressive muscle relaxation therapy. Patients were asked to report the frequency and duration of hot flashes during day and night, at baseline and after ten weeks of treatment, and completed the menopause rating scale.
Results: Eighty-two patients were randomly assigned to receive escitalopram (n=26), PMRT (n=28), and placebo (n=28). PMRT and escitalopram could effectively decrease number and duration of diurnal and nocturnal HFs in patients with breast cancer, with a better effect observed from escitalopram. They could both decrease the total score of MRS.
Conclusion: Both escitalopram ad PMRT can reveal nocturnal and diurnal HFs in terms of frequency and duration in patients with breast cancer.
期刊介绍：
The Journal of Psychosomatic Obstetrics and Gynecology was founded in 1982 in order to provide a scientific forum for obstetricians, gynecologists, psychiatrists and psychologists, academic health professionals as well as for all those who are interested in the psychosocial and psychosomatic aspects of women’s health. Another of its aims is to stimulate obstetricians and gynecologists to pay more attention to this very important facet of their profession.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
